David Miller Award Program

Individuals Supported through the Program

The following individuals have received travel support to attend various meetings through the mechanisms established through the David Miller Awards program. Speakers represent various sectors and viewpoints that enhance each session and help drive the various discussions. For further details on each meeting's scientific program, please follow the link for the corresponding program in each title.

2019 Winter Meeting Program

Risk Assessment Communications—Perspectives from Different Sectors
Elisabeth Anderson, Michigan State University

Evaluating Real and Potential Risks of Allergy or Celiac Disease from Genetically Engineered Crops
Rick Goodman, University of Nebraska

A European Regulatory Perspective on the Qualification of Non-Genotoxic Impurities in Drug Substance/Drug Products
Leon van Aerts, Medicines Evaluation Board

Considerations on Quantification of Uncertainty in Mixtures Studies
Claudio Fuentes, Oregon State University

Review of the Evidence for Thresholds for DNA-Reactive and Epigenetic Experimental Chemical Carcinogens
Gary Williams and Tetyana Kobets, New York Medical College

Modeling:  Issues and Controversies from a Biologist’s Perspective
Lynne Haber, University of Cincinnati

Cannabis in our Food Supply: The Importance of Updating and Implementing the Supply Chain, Manufacturing Practices and Specifications, and Regulatory Oversight
Roger Clemens, University of Southern California


2018 Summer Meeting Program

In Silico Modeling of Liver Toxicity—Where Are We Now?
Mark Hewitt, Wolverhampton University

Adverse Outcome Pathways As Tools to Predict Liver Toxicity in In Vitro Models
Mathieu Vinken, Vrije Universiteit Brussels

Hexabromocyclododecane (HBCD): A Case Study Applying Tiered Testing for Human Health Risk Assessment
Carole Yauk, Health Canada

Examination of the Acute Oral versus Acute Dietary Testing in Avian Risk Assessment Conclusions
Gina Hilton, PETA International Science Consortium

The Adverse Outcome Pathway: A Framework Supporting 21st Century Toxicology
Gary Ankley, US EPA-ORD

Defining Points-of-Departure from New Approach Methods
Katie Paul Friedman, US EPA-NCCT

Adversity in the Light of REACH
Helmut Greim, Technical University of Munich

A Perspective from Industry—Adverse Effects As the Basis for Regulatory Decisions: What Is Adverse?
Rebecca Clewell, ToxStrategies, Inc.

A View on Adverse Effects and Decision Making at US FDA-CFSAN
Antonia Mattia, US FDA-CFSAN

Bioaccumulation of PFASs in Terrestrial Species and Marine Mammals: Canadian Regulatory Perspective
Jessy Kurias, Environment and Climate Change Canada

Relevance of Wildlife Bioaccumulation Data to Human Health Protection
Susanne Brander, Oregon State University


2018 Winter Meeting Program

Using Computational Data and High-Throughput Testing (ToxCast Data) in Support of the KCC
Weihsueh Chiu, Texas A&M University

Case Studies for Integrating Data Collected to Build MOA/AOP and Identify Data Gaps
Nikolai Chepelev, Health Canada

Grouping of UVCBs Using Chemical-Biological Read-Across: Case Study of Petroleum Substances
Ivan Rusyn, Texas A&M University

Research Challenges Associated with PFASs: Ubiquitous Multisystem Toxicants
Jamie Dewitt, East Carolina University

High-Throughput Modeling of Near- and Far-Field Exposure to Chemicals in Consumer Products
Olivier Jolliet, University of Michigan

Evaluation of Therapeutics for the Treatment of Severely-Debilitating or Life-Threatening Diseases
Jennifer Goldman, Rush University